Health Care

Blog

The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition

The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

Greater Price Transparency Will Improve Affordability

Inefficiencies plague our current healthcare system. Politicians are quick to blame these problems on the market and subsequently advocate for ever greater government control. But government programs, which are already major players in the healthcare market, provide lousy insurance for patients and undermine the viability of doctors and hospitals. Expanding ...
Commentary

Private Efforts Not Public Committees Will Generate Healthcare Savings

Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Blog

Read part 1 of a 3 part series on drug pricing

Conspiracies Aside, Drug Company Profits Are Average

Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

No, Donald Trump didn’t just slash Medicaid

Republicans’ One Big Beautiful Bill Act is now law. Democrats have wasted no time accusing the GOP of enshrining devastating “cuts” to Medicaid, the joint federal-state entitlement that provides health coverage for low-income Americans. That’s rubbish. The measure takes steps to restrain Medicaid’s rampant growth in recent years so that ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Blog

The U.S. Drug System Strikes a Reasonable Balance Between Incentivizing Innovation and Promoting Competition

The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics ...
Commentary

Trump Must Shut Down Counterfeit Weight-Loss Drugs

Americans looking to lose weight are increasingly turning to the internet. And they’re being duped. Telehealth startups and fly-by-night pharmacies are peddling what look like cheap, convenient versions of blockbuster drugs like Ozempic and Wegovy. But many of these offerings are neither authentic nor safe. They’re “compounded” copies — knockoffs ...
Commentary

Greater Price Transparency Will Improve Affordability

Inefficiencies plague our current healthcare system. Politicians are quick to blame these problems on the market and subsequently advocate for ever greater government control. But government programs, which are already major players in the healthcare market, provide lousy insurance for patients and undermine the viability of doctors and hospitals. Expanding ...
Commentary

Private Efforts Not Public Committees Will Generate Healthcare Savings

Passed as part of the Affordable Care Act (ACA), the Center for Medicare & Medicaid Innovation (CMMI) was allocated $10 billion in 2011 for the first decade of its existence. It has been allocated hundreds of millions more since. The purpose of the program is to create payment models that ...
Commentary

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

Buried within the One Big Beautiful Bill Act, which President Donald Trump signed into law July 4, is a provision that could improve or even save the lives of the 30 million Americans suffering from rare diseases. That provision is the Orphan Cures Act, which exempts certain drugs that treat ...
Commentary

One Big Beautiful Bill: A Fiscal Lifeline for Medicaid, Taxpayers

The “One Big Beautiful Bill” Act (OBBBA) signed into law by President Donald Trump on July 4 is set to help pull America’s healthcare system back from the brink of fiscal disaster. Read the entire op-ed here.
Blog

Read part 1 of a 3 part series on drug pricing

Conspiracies Aside, Drug Company Profits Are Average

Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is ...
Commentary

The Culprit Impeding Drug Competition Is Not Who The Feds Expected

The Federal Trade Commission and U.S. Department of Justice recently kicked off a series of listening sessions to examine barriers to competition in the drug industry. The title of the first session—”Anticompetitive Conduct by Pharmaceutical Companies”—made it seem that regulators would chiefly investigate biotech firms. Yet by the end, panelists ...
Commentary

No, Donald Trump didn’t just slash Medicaid

Republicans’ One Big Beautiful Bill Act is now law. Democrats have wasted no time accusing the GOP of enshrining devastating “cuts” to Medicaid, the joint federal-state entitlement that provides health coverage for low-income Americans. That’s rubbish. The measure takes steps to restrain Medicaid’s rampant growth in recent years so that ...
Commentary

Cheap Drugs from Canada Can’t Make America Healthy

The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for ...
Scroll to Top